FOLH1 and metastatic neoplasm: Over the last decade, PSMA-ligand PET imaging has redefined benchmarks in PCa imaging [7, 8], excelling in detecting locally relapsed and metastatic disease at very low PSA levels [9] while also providing outcome-relevant semi-quantitative data [10–12].